Methylnaltrexone bromide

Phase 2

Bausch & Lomb (BLCO)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Opioid-induced Constipation

View Full Landscape

Drug Information

Target Indication

Opioid-induced Constipation

Clinical Trial

NCT00640146

Last updated: 10/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/1/2008

Relistor

Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BLCO

Bausch & Lomb

Ophthalmic Goods•North America•NASDAQ

Related Pipeline

brinzolamide ophthalmicPhase 3

Glaucoma

Omeprazole/sodium bicarbonatePhase 3

Gastric Acid

Bromfenac Ophthalmic SolutionPhase 3

Pain

Loteprednol Etabonate Gel (BID)Phase 3

Inflammation

Loteprednol Etabonate OphthalmicPhase 3

Ocular Inflammation

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts